2022 annual financial data
Foghorn Therapeutics 2022 Operating cash flow margin
Direct answer
Operating cash flow margin was 1,006.93%.
Operating income was -117,137,000 USD and net income was -108,873,745 USD.
Operating cash flow was 193,612,000 USD.
Get free Foghorn Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 19,228,000 USD
- Operating income
- -117,137,000 USD
- Net income
- -108,873,745 USD
- Operating cash flow
- 193,612,000 USD